NYSE · Healthcare
Protalix BioTherapeutics, Inc. (PLX)
As-reported financials and recent SEC filings for Protalix BioTherapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$52.7M
Net income
$-6.6M
Net margin
-12.5%
Diluted EPS
$-0.08
ROE
-13.7%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $52.7M | $53.4M | $65.5M | $47.6M | $38.4M |
| Gross profit | $25.8M | $29.1M | $42.5M | $28.0M | $22.0M |
| Operating income | $-5.5M | $3.9M | $10.5M | $-13.0M | $-20.5M |
| Net income | $-6.6M | $2.9M | $8.3M | $-14.9M | $-27.6M |
| Diluted EPS | $-0.08 | $0.04 | $0.09 | $-0.31 | $-0.62 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-25
View on EDGAR →8-K2026-05-21
View on EDGAR →10-Q2026-05-13
View on EDGAR →8-K2026-05-13
View on EDGAR →ARS2026-04-30
View on EDGAR →DEF 14A2026-04-30
View on EDGAR →3/A2026-04-27
View on EDGAR →SCHEDULE 13G/A2026-03-30
View on EDGAR →Largest Healthcare peers
Go deeper on PLX
Search Protalix BioTherapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.